Cadrenal Therapeutics, Inc. Common Stock
CVKDCadrenal Therapeutics, Inc. (CVKD) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular and related diseases. The company is dedicated to advancing treatments that address unmet medical needs, leveraging its expertise in novel drug discovery and development.
Company News
Cadrenal Therapeutics announced research findings demonstrating that its first-in-class 12-LOX inhibitor CAD-1005 can reduce inflammation associated with obesity and Type 2 diabetes. Preclinical studies showed CAD-1005 improved glycemic control, reduced pancreatic β-cell loss, and lowered inflammatory markers. The company believes CAD-1005 could...
Cadrenal Therapeutics acquired VLX-1005, a novel small-molecule inhibitor targeting heparin-induced thrombocytopenia (HIT), from Veralox Therapeutics. The drug candidate has shown promising Phase 2 results and received Orphan Drug and Fast Track designations from the FDA.
Kuick Research released a comprehensive study on the US Orphan Drug Market, projecting market opportunities exceeding $190 billion by 2030, with over 850 orphan drugs in clinical trials and 500 marketed orphan drugs, highlighting significant investment potential in rare disease therapeutics.
The 73rd Emerging Growth Conference is scheduled for July 17-18, 2024, featuring presentations from various companies in the healthcare, technology, and energy sectors.
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results. Compass Minerals Intl posted quarterly adjusted earnings of 5 cents per share, missing market estimates of 26 cents per share. The company’s quarterly sales came in at $341.70 million versus expectations of $357.90 mi...
